糖尿病视网膜病变药物治疗的研究进展  

Progress in medication for diabetic retinopathy

作　　者：刘朝辉[1] 高晓虹[2] 栗改云[1] 马涛[1] 李康[1] 

机构地区：[1]山西医科大学,太原030001 [2]山西省眼科医院,太原030002

出　　处：《国际眼科纵览》2016年第4期272-276,共5页International Review of Ophthalmology

摘　　要：随着糖尿病视网膜病变（diabeticretinopathy，DR）发病机制的深入研究，目前对DR的药物治疗取得了一定的成果，包括糖皮质激素、抗血管内皮细胞生长因子、抗血小板源性生长因子、非甾体类消炎药以及改善视神经功能的药物。目前治疗糖尿病黄斑水肿，玻璃体注药治疗特别是抗血管内皮细胞生长因子药物已逐渐推广。With the update of the pathologic mechanisms of diabetic retinopathy （DR）, currently medication therapy has also made some progress, including eorticosteroids, anti-vascular endothelial growth factor, anti-platelet derived growth factor, non-steroidal anti-inflammatory drugs, as well as drugs to improve the function of the optic nerve. Currently, in the treatment of diabetic macular edema, intravitreal pharmaeo- therapies, especially anti-vascular endothelial growth factor （anti-VEGF） agents, have gained popularity.

关 键 词：糖尿病视网膜病变 糖皮质激素 血管内皮生长因子 血小板源性生长因子 

分 类 号：R587.2[医药卫生—内分泌]